In the quest for the etiology of the delayed union of fractures: the inhibitory role of non-steroidal anti-inflammatory drugs - a complex pharmacological phenomenon? by Mironidou-Tzouveleki, Maria & Dokos, Charalampos





is	a	slow	and	complex	procedure	 that	 involves	a	 re-
generation	 of	 new	bone	 and	 absorption	 of	 old	 bone	





ferentiation	 and	proliferation	of	many	 cellular	 types	
like	chondrocytes,	osteoblasts	e.t.c	are	influenced	by	
genetic	 background,	 systemic	 hormones,	 sensitivity	
to	mechanical	input,	drug	administration,	other	disor-
ders,	cytokines	and	many	more	factors.	Consequent-
ly	 fracture	 healing	 is	 declined	 by	 aging,	 so	 delayed	
union	of	fractures	is	most	common	in	elderly	patients	
(Figure	1).
Fractures	 are	 thoroughly	 classified	 according	 to	
the	 external	 force	 that	 induces	 the	 damage	 of	 bone	
continuity.	They	can	be	due	to	external	violence	and	
pressure	on	the	bone,	continuous	pressures	in	the	area,	
while	 a	 very	 unique	 form	 of	 fractures	 is	 caused	 by	
pathologic	 conditions	 such	 as	 osteoporosis.	Most	 of	
the	times	the	process	of	bone	healing	has	no	distinct	
phases.	In	the	early	stages	there	is	an	increased	blood	
supply	 causing	 a	 hematoma	 in	 the	 area	 of	 fracture.	
This	 is	 observed	 in	 experimental	models	 of	 rodents	
fracture	and	it	is	the	very	first	stage	of	bone	healing.	
Simultaneously	there	is	an	increased	surrounding	by	





and	 that	 is	 the	early	beginning	of	ossification	of	 the	
osteoid.	Bone	remodeling	has	begun,	and	two	levels	
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of	 fibrous	 tissue	 or	 a	 false	 joint	 called	 pseudarthro-
sis.	Through	observations,	non-steroidal	anti-inflam-
matory	 drugs	 (NSAIDs)	 seem	 to	 have	 an	 inhibitory	
role	in	the	whole	bone	healing	process,	from	the	early	
stages	of	angiogenesis	in	bone	fracture	until	the	bone	
remodeling	 final	 stages.	 This	 review	 examines	 and	
analyzes	the	experimental	and	clinical	data	from	the	
use	of	NSAIDs	in	bone	fractures.
PHARMACOLOGY OF NON-STEROIDAL 
ANTI-INFLAMMATORY DRUGS















less.	 After	 many	 unsuccessful	 tries,	 Bayer	 was	 the	





was	 taken	 by	 the	 name	 of	 the	 plant	 Spiraea,	 from	
which	aspirin	was	first	produced2,6,7.
In	1938	the	Lancet	journal	(see	study	from	Douth-
waite AH, Lindott GAM. Gastroscopic observation of 
the effect of aspirin in certain other substances in the 










NSAIDs	 is	 a	 class	 of	 drugs	with	 anti-inflamma-





ulcers,	 nausea,	 diarrhea,	 stomach	 ache,	 gastric	 tract	
Figure 1. Bone	healing	stages	are	not	always	distinct.	Bone	remodeling	process	is	an	established	model	regulated	
by	systemic	and	non-systemic	factors.
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NSAIDs.	 With	 any	 NSAID	 administration	 patients	
must	follow	a	gastric	protection	treatment	scheme.	In	
the	current	medical	bibliography	there	are	many	case	
reports	 and	 clinical	 studies	 of	 gastric	 bleeding	 and	





thesis,	 reduction	 of	 immunity	 defenses,	 gastric	mu-
cosa	protection	and	production	of	cytokines.	Possibly	
there	 is	 a	 dysfunction	 of	 mitochondria	 in	 intestine	
cells	 resulting	 in	an	 increased	permeability	of	 intes-
tine	membrane	and	 invasion	of	bacteria.	 In	 the	 area	
of	injury,	neutrophils	concentrate	and	free	radicals	are	
produced.	 For	 this	 reason	 patients	 that	 take	 a	 small	
amount	 of	 aspirin	 for	 cardiovascular	 problems	must	
have	gastric	protection	medication,	for	example	a	pro-
ton	pump	inhibitor.	Gastric	protection	is	not	necessary	







prostaglandins	 by	 arachidonic	 acid	 (Figure	 2).	 The	
arachidonic	 acid	 (cellular	 membrane	 phospholipids	











function	 (production	 of	 thromboxane	 A
2
).	 COX-2	
involves	 the	 production	 of	 prostaglandins	 that	 take	
part	 in	 inflammatory	processes,	pain	and	renal	func-



















which	 is	 a	 little	bit	 larger	 and	has	a	 second	 internal	
junction	position	for	heavier	substances	in	molecular	
weight.	 Therefore	 selective	 NSAIDs	 with	 different	
molecular	weights	may	 be	 conjugated	 time-depend-
ently	and	non-reversibly	with	COX-1	or	COX-2.	Big	
molecular	 weight	 non-selective	 NSAIDs	 are	 conju-
gated	with	both	the	two	isoforms	of	COX	enzyme	in	
instantly	reversible	way7,12-14.
NSAIDs	 have	 three	 distinct	 features:	 analgesic,	








fore	 their	use	was	 stopped	because	of	 the	unwanted	
effects.	 Meloxicam	 is	 the	 latest	 that	 had	 fewer	 un-
wanted	 effects.	 Phenylbutazon	 is	 a	 pyrazol	 product	
with	anti-inflammatory	action	but	weak	analgesic	and	
antipyretic	properties.	Diclofenac,	ketorolac,	tolmen-






IN THE QUEST FOR THE ANSWER
Animal	 studies	 are	 directed	 to	 one	 preferable	 con-
clusion:	 Conventional	 non-specific	 NSAIDs	 delay	
healing	 in	 complete	 fractures.	The	 best	 documented	
substances	 were	 indomethacin,	 diclofenac,	 naprox-
en,	 ketorolac,	 ibuprofen	 and	 naproxen.	These	 drugs	
caused	slower	fracture	healing	in	early	stages2,14,18-22.	
Fractures	may	 vary	 including	 rat	 forelimb,	 vertebra	





reach	 toxicity	 levels	 in	 experimental	 animal	models	
so	as	to	have	fracture	delayed	union.	A	possible	cause	
of	 this	fact,	 that	 is	 less	known	by	the	researchers,	 is	
that	COX	inhibitors	are	metabolized	very	quickly	by	
hepatic	enzymes	(first	 route	of	metabolism),	so	 they	
present	 low	 final	 serum	 concentrations	 relevant	 to	
bone	healing	fracture6,8,23.
Indomethacin	followed	by	ketorolac	both	appeared	






have	very	 impressive	 results.	COX-2-/-	mice’s	 endo-
chondral	 ossification	 was	 delayed	 compared	 with	
COX-1	knockout	mice.	It	seems	that	COX-2	selective	











levels	 of	 bone	morphogenetic	 protein	 -	 2	 (BMP-2),	



















genic	 proliferation	 at	 the	 early	 stages	 of	 bone	 heal-
ing14,25-29.	Another	mechanism	that	may	involve	COX-
2	and	bone	 repair	 indicates	 that	COX-2	maintains	a	
population	 of	mesenchymal	 stem	 cells	 in	 pre-osteo-
blast	state,	so	during	injury	cases	like	bone	fractures,	
COX-2	may	 affect	 through	 regulation	 of	 cbfa1	 and	
osterix	 in	 an	 upstream	 of	 reactions	 with	 osteoblast	




topic	 bone	 formation	 after	 hip	 arthroplasty,	 accord-
ing	 to	 several	 studies.	This	 is	 an	advantage	 in	 these	
situations,	but	brings	us	in	front	of	a	debate	whether	
NSAIDs	 inhibit	 fracture	 healing.	Nevertheless	 there	
is	not	yet	a	defined	answer	whether	NSAIDs	 inhibit	
bone	healing	process.	Risk	factors	that	adversely	may	




ciated	with	 non-union	 cases18,30.	Most	 studies	 found	
no	significant	differences	 in	 fracture	 risk	and	use	of	
























Hypoprothrombithemia,	 low	 platelet	 concentration	 with	
high	risk	of	gastric	bleeding.






Decreased	 clearance	 of	 methotrexate	 in	 kidney	 and	 in-
creased		levels	of	methotrexate	in	serum	-	toxicity.
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established	results	come	only	from	animal	studies	so	
there	is	a	need	for	more	studies	in	clinical	level.






key	 role	 should	be	 considered.	Despite	 the	 fact	 that	







fracture,	 therefore	 orthopaedists	 must	 be	 very	 care-
ful	in	the	use	of	NSAIDs	in	these	cases.	Maybe	new	
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